Pathways’ Picks February 10: Updates from China, Nomination Chatter, DigHealth Scrutiny

article image

In this week’s roundup: Updates on China’s device approval numbers; a look at leading candidates for top FDA and CMS jobs; Sen. Cassidy probes CDRH on artificial intelligence/machine learning plans; COVID-19 relief moves forward; and DME bidding program hits more barriers.

China released its 2020 approval stats and its plans to revise aging device guidance documents. In the US, chatter around FDA and CMS nominations builds, COVID-19 relief proceeds, and the DME Medicare competitive bidding program appears to be languishing. More in this edition of Pathways’ Picks.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: